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OBJECTIVE: To evaluate process and effects in an imple-
mentation study after the RCT, regarding a health edu-
cation and physical exercise program for older adults
with osteoarthritis (OA) of the knee. Implementation
studies are recommended to assess the feasibility and
effectiveness in real life conditions of health education
programs, after being tested in RCTs. METHODS: Three
types of primary health care providers co-operated in the
study, as well as four major health insurers, anticipating
the future integration of the program in their insurance
policy. Local branches of the providers (n = 18) supported
with a program manual and implementation guidelines,
delivered the program to 157 subjects. Inclusion criteria
were older adults of >55 years of age, with diagnosed OA
of knee. Implementation activities were monitored with
registration forms, questionnaires and interviews with 
the providers. Program-participants completed question-
naires before and immediately after participation. This
design was thought to be adequate, given the objective to
identify the effects of the program in real life conditions
after the RCT. Outcome parameters were pain, mobility,
self-efﬁcacy and OA-knowledge and health care utilisa-
tion. RESULTS: Positive effects occurred for pain (p =
0.06), self-efﬁcacy (p = 0.06), OA-knowledge (p = 0.00),
use of medication (p = 0.00), treatment by phsyiothera-
pist (p = 0.01) and consultation of the general practitioner
(p = 0.01). Effect sizes reported in the former RCT and
the current study, were comparable. All three kinds of
providers contributed to an equal extent to the outcomes.
The implementation strategy contributed to the ﬁdelity in
program delivery. CONCLUSIONS: This implementa-
tion study emphasised that planned co-operation between
researchers, practitioners and policy-makers can con-
tribute to the transfer of research results. In doing so, a
widely recognised gap between research and practice can
be bridged.
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OBJECTIVE: To adapt and validate an Estonian version
of the RAQoL. The measure, developed in the UK,
assesses rheumatoid arthritis (RA) speciﬁc quality of life
(QoL). The aim of the cultural and linguistic adaptation
of the RAQoL is to produce a version with equally good
psychometric properties to existing language versions.
METHODS: Translation consisted of two stages. The
ﬁrst involved six Estonians with non-medical back-
grounds and good English who worked together to agree
a ﬁrst translation of the questionnaire. The group was
attended by one of the authors of the RAQoL who
advised on the precise meaning of items. The appropri-
ateness of wording and clarity of content of the transla-
tion were then evaluated by six healthy people of average
educational level. In the next stage of adaptation 15 RA
patients were interviewed to determine face and content
validity. RESULTS: No major problems were found in
translating the questionnaire into Estonian. Patient inter-
views indicated that the content of the RAQoL was highly
appropriate for Estonian patients, despite differences in
health service provision and culture from the UK. CON-
CLUSION: This is the ﬁrst occasion on which a disease-
speciﬁc QoL questionnaire has been adapted into
Estonian and the results are very encouraging. The ﬁnal
stage of the adaptation will be a formal survey of repro-
ducibility and construct validity of the adapted measure.
The novel aspect of the survey is that data will be col-
lected by means of patient interview and will include a
clinical assessment of functional status and disease activ-
ity at the time of interview. It is intended that the RAQoL
will be used to evaluate interventions and to be included
with the HAQ in a register of patients with rheumatoid
arthritis.
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OBJECTIVES: The aim of this study was to use patients
currently being treated for osteoarthritis to determine 
the utility values for different health outcomes associated
with the use of non-steroidal anti-inﬂammatory drugs
(NSAIDs) or paracetamol. METHODS: A total of 85
patients currently being treated with NSAIDs and/or
paracetamol were recruited to value ﬁve health state sce-
narios using the Assessment of Quality of Life (AQOL)
multi-attribute utility (MAU) instrument. The ﬁve health
states described various health states of osteoarthritis
with varying possible NSAID-related side effects. The
health states were developed using published clinical trial
data and expert opinion. The participant, using the
AQOL MAU, valued each health state. Mean utility
values were derived for each health state using the AQOL
scoring algorithm. RESULTS: Osteoarthritis without gas-
trointestinal (GI) side effects produced the highest mean
utility score (0.69) while the complicated perforation,
ulcer or bleed (PUB) health state produced the lowest
utility (0.20). Higher utility values were seen in the
uncomplicated PUB (0.38) and minor NSAID-type GI
complications (0.48) health states. The health state
describing osteoarthritis managed with paracetamol pro-
duced a lower utility than the health state describing
osteoarthritis managed with traditional NSAIDs (0.36 
vs 0.69)—a result consistent with the relative efﬁcacy of
NSAIDs and paracetamol in the treatment of osteoarthri-
tis. CONCLUSION: The results suggest that there is
potential to improve the quality of life of osteoarthritis
729Abstracts
sufferers. The magnitude of the quality of life improve-
ments estimated in this study allows therapies, which
reduce the burden of GI toxicities to be evaluated in a
cost-utility framework.
OSTEOPOROSIS—Cost Studies
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OBJECTIVE: To develop an epidemiological model of
osteoporosis and its sequelae to estimate the current and
future prevalence and costs of osteoporotic fractures 
to the NHS. METHODS: A decision-analytic model
employing a Markov process was constructed using MS
Excel. The model incorporates key epidemiological data
and modelled treatment pathways with published cost
data of fracture/osteoporosis treatment. The model esti-
mates the current population of post-menopausal women,
using prevalence data from the European Vertebral
Osteoporosis Study (EVOS), along with current usage of
anti-fracture medication. The rate of incident fractures
from the European Prospective Osteoporosis Study
(EPOS) is modiﬁed by the increased risk of subsequent
fracture and the protection gained with treatment. Costs
were based on Dolan & Torgerson (1998): Hip frac-
ture £16,000 (1st year of fracture); vertebral fracture
£321–£3,543; wrist fracture £394; other fracture £1,138.
RESULTS: The model estimates almost 345,000 fractures
will occur in 2003, resulting in costs of over £800 million.
Vertebral fractures are the most common type, with an
estimated 177,000 fractures in 2003 at a cost of £72
million. Hip fractures account for approximately 83% of
the total costs, with an estimated 40,000 fractures costing
£634 million. Around 65,000 wrist fractures are esti-
mated, at a cost of approximately £25 million, with a
further 61,000 “other” fractures costing around £70
million. This model does not currently include males, and
hence these results underestimate the true cost of osteo-
porosis to the NHS. CONCLUSIONS: The costs of osteo-
porosis fractures are substantial. This results from a high
incidence of fractures and expensive health care (primar-
ily secondary care). Vertebral fractures are over four times
as common as hip fractures, which indicates a substan-
tial health burden, although hip fractures are more costly.
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OBJECTIVE: To develop an epidemiological model of
osteoporosis and its sequelae to estimate the current and
future prevalence of osteoporotic fractures in females
aged 45 years and over, in different European countries.
METHODS: A decision-analytic model employing a
Markov process was constructed using MS Excel.
Country-speciﬁc population projection ﬁgures were com-
bined with data from major European epidemiological
studies to estimate the current and future prevalence of
osteoporotic fractures in women. Regional prevalence
data came from the European Vertebral Osteoporosis
Study (EVOS) and incidence data from the follow-up
European Prospective Osteoporosis Study (EPOS).
Results for France, Germany (Western Europe), Italy,
Spain (Southern Europe), Sweden, and Finland (Scandi-
navia) will be presented. RESULTS: A total of 1.8 million
osteoporotic fractures are estimated to occur in women
aged 45 years and older in these 6 countries in 2003. Ver-
tebral fractures are the most common type, accounting
for almost 1.1 million of all fractures. It is also estimated
there will be almost 250,000 wrist fractures, 220,000hip
fractures and 290,000 “other” fractures. The overall rates
of fractures are substantially higher for the Scandinavian
countries than for the other countries: France 28.2/1000,
Germany 28.4/1000, Italy 28.8/1000, Spain 31.0/1000,
Finland 61.9/1000, and Sweden 71.0/1000 women.
CONCLUSIONS: Osteoporotic fractures are an impor-
tant cause of morbidity in these countries. Vertebral frac-
tures are the most common type, thus warranting study
of their economic and health impact. The variations in
rate of fracture between regions reﬂect predominantly 
the differing prevalence and incidence rates found in the
EVOS and EPOS studies, and to a lesser extent, the
country-speciﬁc age structures.
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OBJECTIVES: To estimate the hospitalisation costs of
accidental injuries in the European Union (EU) resulting
from the use of benzodiazepines. METHODS: Design: A
case-control study on the association between accidental
falls and benzodiazepines. Setting: Community–dwelling
inhabitants over 55 years of deﬁned areas in The Nether-
lands covering the period 1985–2000. All analyses were
performed from the perspective of a third-party payer.
Studies: Risk and exposure data were obtained from the
Dutch PHARMO system, a population-based register of
drug-dispensing records and hospital records. The popu-
lation attributable risk (PAR) was calculated with the age
speciﬁc prevalence estimates of benzodiazepine use and
the corresponding odds ratios (OR) obtained from a case
